ENGLEWOOD, Colo., Jan. 14, 2021 /PRNewswire/ -- Zynex, Inc.
(NASDAQ: ZYXI), an innovative medical technology company
specializing in the manufacture and sale of non-invasive medical
devices for pain management, stroke rehabilitation, cardiac
monitoring and neurological diagnostics, today reported it has
filed for a provisional patent for a noninvasive sepsis
monitor.
Thomas Sandgaard, CEO of Zynex
said: "Sepsis is one of the biggest problems in hospitals today. In
the U.S. alone, over 1.7 million adults will develop sepsis
annually with nearly 270,000 deaths as a result. Conventional
patient monitors give insufficient advance warning of deteriorating
patient health or the onset of potentially serious physiological
conditions resulting from sepsis. A sepsis monitor that
noninvasively measures patient condition and provides caregivers
with an advanced warning or prediction of the onset of sepsis would
be beneficial. A sepsis monitor may also be configured to provide
or facilitate automatic intervention or treatment of sepsis and
conditions resulting from sepsis. This sepsis monitor is capable of
detecting potential sepsis in patients earlier than traditional
methods, which has the potential to save lives. I believe the
sepsis monitor will be a great complement to our CM-1500 Blood
Volume Monitor, non-invasive detection of fluid balance in hospital
settings."
Sepsis is a life-threatening medical condition characterized by
the body-wide inflammatory response or reaction that presents in
response to infection. The inflammatory response triggered by the
immune reaction can cause body-wide tissue damage, even to areas
not local to the original infection. Bacterial infections are the
most common cause of sepsis, but sepsis can also be caused by
fungal, parasitic, or viral infections. As an ineffectively treated
infection progresses, toxins from the infection may circulate in
the blood stream, causing damage to other organs (such as the
brain, heart, lungs, kidneys, liver, etc.) and tissues. As the
damage progresses, septic shock and a fatal decline in blood
pressure may occur; patients with additional medical conditions and
risk factors have increased likelihood of death.
Sepsis treatment spans multiple days to weeks, often in an
intensive care environment and is detected through blood cultures,
blood-gas analysis, kidney and other organ functional tests,
platelet and white blood cell counts, additional imaging, urine
testing, cerebrospinal fluid tests, etc.
The signs and symptoms of sepsis often may be subtle. The low
survival rate of patients with severe sepsis indicates that current
sepsis identification strategies, tools, and methods may be
lacking.
About Zynex, Inc.
Zynex, founded in
1996, markets and sells its own design of electrotherapy medical
devices used for pain management and rehabilitation; and the
company's proprietary NeuroMove device designed to help recovery of
stroke and spinal cord injury patients. Zynex also has a blood
volume monitor for use in hospitals and surgery centers. For
additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to
the future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore you should not rely on any of
these forward looking statements. The Company makes no
express or implied representation or warranty as to the
completeness of forward looking statements or, in the case of
projections, as to their attainability or the accuracy and
completeness of the assumptions from which they are derived.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain CE marking of new products, the acceptance of new
products as well as existing products by doctors and hospitals,
larger competitors with greater financial resources, the need to
keep pace with technological changes, our dependence on the
reimbursement for our products from health insurance companies, our
dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force, the impact of
COVID-19 on the global economy and other risks described in our
filings with the Securities and Exchange Commission including but
not limited to, our Annual Report on Form 10-K for the year
ended December 31, 2019 as well as our quarterly reports
on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Amato And Partners,
LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-announces-filing-of-patent-for-sepsis-monitor-301208385.html
SOURCE Zynex